Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
694 | 3091 | 46.1 | 90% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
40 | 31853 | AIDS RESEARCH AND HUMAN RETROVIRUSES//HIV 1//AIDS |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CCR5 | Author keyword | 245 | 45% | 13% | 406 |
2 | MARAVIROC | Author keyword | 101 | 57% | 4% | 121 |
3 | CCR5 ANTAGONIST | Author keyword | 75 | 75% | 2% | 54 |
4 | CCR5 ANTAGONISTS | Author keyword | 67 | 80% | 1% | 41 |
5 | VICRIVIROC | Author keyword | 45 | 80% | 1% | 28 |
6 | CORECEPTOR | Author keyword | 44 | 49% | 2% | 66 |
7 | HIV TROPISM | Author keyword | 38 | 86% | 1% | 19 |
8 | TROPISM | Author keyword | 25 | 25% | 3% | 90 |
9 | CCR2 64I | Author keyword | 24 | 91% | 0% | 10 |
10 | CORECEPTOR SWITCH | Author keyword | 23 | 100% | 0% | 10 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CCR5 | 245 | 45% | 13% | 406 | Search CCR5 | Search CCR5 |
2 | MARAVIROC | 101 | 57% | 4% | 121 | Search MARAVIROC | Search MARAVIROC |
3 | CCR5 ANTAGONIST | 75 | 75% | 2% | 54 | Search CCR5+ANTAGONIST | Search CCR5+ANTAGONIST |
4 | CCR5 ANTAGONISTS | 67 | 80% | 1% | 41 | Search CCR5+ANTAGONISTS | Search CCR5+ANTAGONISTS |
5 | VICRIVIROC | 45 | 80% | 1% | 28 | Search VICRIVIROC | Search VICRIVIROC |
6 | CORECEPTOR | 44 | 49% | 2% | 66 | Search CORECEPTOR | Search CORECEPTOR |
7 | HIV TROPISM | 38 | 86% | 1% | 19 | Search HIV+TROPISM | Search HIV+TROPISM |
8 | TROPISM | 25 | 25% | 3% | 90 | Search TROPISM | Search TROPISM |
9 | CCR2 64I | 24 | 91% | 0% | 10 | Search CCR2+64I | Search CCR2+64I |
10 | CORECEPTOR SWITCH | 23 | 100% | 0% | 10 | Search CORECEPTOR+SWITCH | Search CORECEPTOR+SWITCH |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CORECEPTOR USAGE | 192 | 53% | 8% | 257 |
2 | SYNCYTIUM INDUCING PHENOTYPE | 189 | 62% | 6% | 194 |
3 | CHEMOKINE RECEPTOR GENE | 175 | 75% | 4% | 125 |
4 | BIOLOGICAL PHENOTYPE | 152 | 62% | 5% | 159 |
5 | CCR5 | 140 | 34% | 11% | 340 |
6 | TROPIC HIV 1 | 91 | 58% | 3% | 104 |
7 | MARAVIROC | 89 | 60% | 3% | 96 |
8 | VICRIVIROC | 85 | 100% | 1% | 26 |
9 | CORECEPTOR | 82 | 35% | 6% | 194 |
10 | CHEMOKINE RECEPTOR CCR5 | 79 | 51% | 4% | 112 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease | 1999 | 1468 | 212 | 77% |
European guidelines on the clinical management of HIV-1 tropism testing | 2011 | 112 | 51 | 88% |
Entry inhibitors in the treatment of HIV-1 infection | 2010 | 112 | 148 | 47% |
The CCR5 and CXCR4 coreceptors - Central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection | 2004 | 270 | 216 | 51% |
Entry inhibitors and their use in the treatment of HIV-1 infection | 2013 | 26 | 187 | 52% |
CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities | 2012 | 27 | 46 | 72% |
HIV population genotypic tropism testing and its clinical significance | 2012 | 16 | 54 | 94% |
Clinical use of CCR5 inhibitors in HIV and beyond | 2011 | 34 | 127 | 68% |
Correlation of coreceptor usage and disease progression | 2012 | 17 | 63 | 86% |
Genotypic Determination of HIV Tropism - Clinical and Methodological Recommendations to Guide the Therapeutic Use of CCR5 Antagonists | 2010 | 26 | 31 | 94% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CLIN VIROIMMUNOL | 6 | 18% | 1.0% | 31 |
2 | PROGRAM MOL MED AIDS | 6 | 100% | 0.1% | 4 |
3 | VIROL PREVENT MED | 4 | 27% | 0.5% | 14 |
4 | UR543 | 4 | 67% | 0.1% | 4 |
5 | UNIT IMMUNOBIOL HIV | 4 | 50% | 0.2% | 6 |
6 | UNIT HUMAN VIROL | 4 | 21% | 0.5% | 15 |
7 | HYG VIROL | 3 | 39% | 0.2% | 7 |
8 | HIV S | 3 | 100% | 0.1% | 3 |
9 | ID DMPK | 3 | 100% | 0.1% | 3 |
10 | SEQUENCING ANTIVIRAL DRUG MONITORING UNIT | 3 | 100% | 0.1% | 3 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000205405 | UNITE RETROVIROL MOL//ENTROPY EVOLUTION RATE//HIV 1 MOTHER TO CHILD TRANSMISSION |
2 | 0.0000148338 | ENFUVIRTIDE//GP41//T 20 |
3 | 0.0000108599 | IAVI NEUTRALIZING ANTIBODY//DUKE HUMAN VACCINE//HIV AIDS VACCINE IMMUNOL IMMUNOGEN DISCOVER |
4 | 0.0000107053 | CCR2 ANTAGONIST//CCR2//CCR2 ANTAGONISTS |
5 | 0.0000092393 | HIV 1 GP41//GP120 CD4 INTERACTION//CD4 RECEPTOR |
6 | 0.0000072323 | UF SIDA//KODECYTE//ESA CNRS 6033 |
7 | 0.0000071769 | CXCR4//CXCR7//CXCL12 |
8 | 0.0000071647 | SIV//SHIV//SIMIAN IMMUNODEFICIENCY VIRUS |
9 | 0.0000068838 | EMI U 9922//UNITE PHYSIOPATHOL INFECT LENTIVIRALES//DIPARTIMENTO IGIENE MED PREVENT SANITA PUBBL |
10 | 0.0000068078 | EXPOSED UNINFECTED//HESN//IMMUNOBIOL HIV UNIT |